What Happened? | Last week, the popular weight loss drug Wegovy became available to American consumers in pill form. Wegovy, which is also known by its generic name semaglutide or Ozempic, is manufactured by the Danish pharmaceutical company Novo Nordisk and had previously only been available as an injection. | The pill will be available through U.S. pharmacies such as CVS, Costco, Amazon, and other providers. Sales of the pill form of Wegovy in the United States became possible after the U.S. Food and Drug Administration approved the pill for use in December 2025. | Why it Matters | Wegovy has become one of the most popular drugs in the United States and the most popular weight loss drug. According to some estimates, nearly twelve percent of the U.S. population were taking Wegovy by the end of 2025, which equals roughly forty million people in the U.S. alone. Until now, Wegovy has only been available as an injection or shot, but Novo Nordisk hopes the oral form of the medication will increase sales in 2026. | | | You might call RAD Intel the ROAS King. It powers Fortune 1000 brands and agencies worldwide. Valuation up 5,000%+ in four years*. NASDAQ ticker $RADI reserved. Backed by Adobe and insiders from Google. Recurring seven-figure contracts secured. Sales already 2× in 2025. Shares are just $0.85. Invest in RAD Intel before the next share-price change. | π Invest Today at $0.85/Share. | | Pills offer several advantages over injections. Wegovy is usually taken weekly, and for patients who took injections, each time they had to either buy a new injector or go to a health care provider to receive the shot, which can be both time-consuming and more expensive. In addition, shots can be painful for some because they require a needle piercing the skin. By contrast, pills can simply be swallowed, and they do not require any other paraphernalia such as injectors. | The widespread use of Wegovy has had a significant impact on obesity. Obesity is linked to several chronic illnesses such as diabetes and heart disease, in addition to increased back and joint pain. Since 2022, which is when Wegovy came on the market, obesity rates in the United States have dropped from forty percent to thirty seven percent, the first annual decrease in decades. Obesity increases health care costs and worsens chronic illnesses, making it doubly expensive for individuals and national health care systems. | Wegovy works by mimicking a naturally occurring hormone known as glucagon-like peptide, or GLP-1. This hormone regulates appetite and when more of the hormone or drug is present, the brain tells the body no more food is needed, which stops people from feeling hungry, even if they haven't eaten much recently. People taking Wegovy and other GLP-1 drugs have a sustained and decreased appetite, which causes them to consume fewer calories leading to weight loss. | How it Affects You | Wegovy has proven effective at helping millions of people achieve weight loss, and the pill form could increase those numbers in addition to generating more revenue for Novo Nordisk. The drug does have side effects, with some recipients of the drug reporting muscle loss, nausea, and decreased sex drive. | | More breaking news below… | Google's AI Overview feature provided dangerous medical misinformation about liver tests and other health topics, prompting removal after an investigation exposed serious accuracy problems. Read more here… | Justice Department investigates Fed Chair Powell amid Trump's pressure for rate cuts, sparking bipartisan concerns about central bank independence and market stability. Read more here… | Iran's ruling regime institutes harsh security crackdown against protesters as hundreds are feared dead. Read more here… | Policy has eased, but money hasn't gotten easy. Read more here… | | *Disclaimer: This is a paid advertisement for RAD Intel made pursuant to Regulation A+ offering and involves risk, including the possible loss of principal. The valuation is set by the Company and there is currently no public market for the Company's Common Stock. Nasdaq ticker "RADI" has been reserved by RAD Intel and any potential listing is subject to future regulatory approval and market conditions. Brand references reflect factual platform use, not endorsement. Investor references reflect factual individual or institutional participation and do not imply endorsement or sponsorship by the referenced companies. Please read the offering circular and related risks at invest.radintel.ai. |
|
.png)
No comments:
Post a Comment